Occlutech Holding AG
21.12.2021 08:02:34 CET | ACCESS Newswire | Press release
SCHAFFHAUSEN, SWITZERLAND / ACCESSWIRE / December 21, 2021 / Occlutech Holding AG
Occlutech Holding AG ("Occlutech" or the "Company"), a leading specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of shares (the "Private Placement") of 450 MSEK before transaction costs, to the Fourth Swedish National Pension Fund, Carnegie Private Banking and certain other investors. The purpose of the issue is to support Occlutech's significant opportunities in the U.S. market, continue to facilitate Occlutech's growth, as well as to repay maturing loans.
Occlutech has completed a Private Placement corresponding to SEK 450 million before transaction costs to finance the Company's growth ambition. The Private Placement attracted a lot of interest and was led by the Fourth Swedish National Pension Fund and Carnegie Private Banking.
Occlutech sells its products in over 85 countries, whereby the European market is dominant with a strong market share. The Company has a clear growth strategy, both in existing markets as well as through further global expansion. In particular, the U.S. market is expected to have significant growth opportunities for Occlutech's products and is therefore considered a future key market.
Earlier this year Occlutech set up a subsidiary in the U.S., focusing on clinical, regulatory, logistics, and supporting distribution. The Company also received granted conditional approval from the U.S. Food and Drug Administration (FDA) for IDE applications to conduct a pivotal Patent Foramen Ovale (PFO) study for Occlutech's PFO Occluder and a pivotal study for Occlutech's Atrial Flow Regulator (AFR) device for heart failure. The Company anticipates receiving an FDA market approval for the U.S. in 2026.
"Occlutech's sales continue to progress with good momentum, confirming the quality and competitiveness of the company's products. The U.S. market represents a significant growth potential for Occlutech and the financial strength that comes from the Private Placement allows Occlutech to continue with clinical trials for regulatory approvals in the U.S. for both the AFR device for heart failure and the PFO Occluder for stroke prevention", says Sabine Bois, CEO of Occlutech.
"Occlutech's Board welcomes the Fourth Swedish National Pension Fund and Carnegie Private Banking, together with other investors as new shareholders in Occlutech. The successful Private Placement of SEK 450 million, before transaction costs, confirms the confidence in Occlutech's products and market potential, with the aim of generating long-term value creation for both society and shareholders", says Marianne Dicander Alexandersson, Chairperson of Occlutech.
According to a market study, by the consulting firm Roland Berger, the developing market for interatrial shunt devices, such as Occlutech's Atrial Flow Regulator for heart failure, has an estimated market potential of about €3.9 billion in 2021 in the U.S. and EU5 (France, Germany, Italy, Spain, United Kingdom). The study also indicates that the global addressable market within structural heart disease devices is estimated at approximately €350-400 million in 2021 and is expected to grow around 10 percent annually in the next five years. Births and increased treatment adoption drive structural heart volumes while aging populations as well as lifestyle diseases, such as diabetes and overweight, cause heart failure volumes to increase.
Advisers
Carnegie Investment Bank AB (publ) acted as sole financial adviser to Occlutech. Baker McKenzie acted as the legal adviser to Occlutech as to Swedish and Swiss law.
Contacts
Sabine Bois
CEO
E-mail: sabine.bois@occlutech.com
Lars Wadell
CFO
Email: lars.wadell@occlutech.com
Phone: +46 763 20 04 34
Image Attachments
Sabine Bois CEO
Marianne Dicander Alexandersson Chairperson
Attachments
Occlutech has successfully completed a Private Placement of 450 MSEK to support growth
SOURCE: Occlutech Holding AG
View source version on accesswire.com:
https://www.accesswire.com/678813/Occlutech-has-Successfully-Completed-a-Private-Placement-of-450-MSEK-to-Support-growth
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AI Trading Changing Stock, Gold, and Forex Trading Market: Funds Coin's Multi-Agent Trading Update Dominates20.5.2026 11:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 20, 2026 / Ten years ago, algorithmic trading was the exclusive territory of investment banks and hedge funds. Today, a retail trader with $100 and a smartphone can access the same class of automated execution that once required a team of quants and millions in infrastructure. That's not an exaggeration. It's the shift that's quietly reshaping stock and forex markets, and AI trading agents are at the center of it. The Old Way Is Breaking Down Manual trading made sense when markets moved slowly enough for humans to keep up. That world no longer exists. Forex markets process over $7 trillion in daily volume. Crypto trades around the clock across hundreds of exchanges. Stock prices react to news in milliseconds. The information moves faster than any individual trader can process, and emotions, such as fear, greed, and hesitation, make an already difficult job even harder. The traders who thrived in this environment were either exceptionally disciplined o
Karbon-X and Evertrak Sign Letter of Intent to Advance Infrastructure-Linked Plastic Waste Reduction Credit Initiative19.5.2026 19:45:00 CEST | Press release
Proposed initiative would evaluate the potential generation of Verra-aligned Plastic Waste Reduction Credits for approximately 200,000 railroad ties made from recycled plastic currently installed across railroad infrastructure in North America. CALGARY, AB / ACCESS Newswire / May 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary environmental markets, today announced the signing of a Letter of Intent with Evertrak LLC ("Evertrak"), the leading manufacturer of Glass Fiber Reinforced Composite (GFRC) railroad ties made from recycled plastic, to explore an infrastructure-linked Plastic Waste Reduction Credit ("PWRC") initiative under Verra's Plastic Waste Reduction (PWR) Standard. Across North America, 20 million railroad ties made from wood are replaced annually. Approximately 4-6 million of those ties are less than 12 years old. Safe, resilient, and efficient railroad infrastr
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom